Get notified when RNAZ files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Material Weakness (worsened) — Material weaknesses in internal controls persist since 2021; current filing cites acquisition-related accounting issues, though management claims 'small number' remain unremediated versus 'many' in prior year.
  • Going Concern (unchanged) — Going-concern language removed from MD&A (cash runway extended to year-end 2026 vs. mid-Q2 2025), but Risk Factors section retains substantial doubt disclosure with auditor flag.
NASDAQ: RNAZ Transcode Therapeutics, Inc. 10-K

TransCode acquires melanoma vaccine, raises $25M, completes Phase 1a; cash extends to year-end 2026

Filed April 15, 2026 · Period ending December 31, 2025 · Compared to 10-K Apr 15, 2025 · ~2 min read

Key Changes

  • high

    Acquired Polynoma's melanoma vaccine Seviprotimut-L (Phase 2-stage, FDA Fast Track) for 11.5M shares; DEFJ invested $25M concurrent with deal, improving cash from $5.8M to $17.8M and extending runway from mid-Q2 2025 to year-end 2026.

    MD&A: Polynoma Acquisition & Liquidity verify on EDGAR →
  • high

    Completed Phase 1a trial of TTX-MC138 in 16 patients with no dose-limiting toxicities; positive pharmacodynamics across all cohorts. Phase 2a collaboration with Quantum Leap (PRE-I-SPY platform) to start Q2 2026, targeting colorectal cancer minimal residual disease.

    Business: Phase 1a Completion & PRE-I-SPY verify on EDGAR →
  • high

    Licensed Unleash's oncolytic virus platform (UIO-524, 525, 526) for 1.1M shares; lead candidate UIO-524 targets muscle-invasive bladder cancer with multi-cytokine immune payload. Expands pipeline beyond RNA therapeutics into viral immunotherapy.

    Business: Unleash License verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.

Partner

Trade RNAZ commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify